DEP domain containing 1 predicts prognosis of hepatocellular carcinoma patients and regulates tumor proliferation and metastasis

Abstract

DEP domain containing 1 (DEPDC1) protein is a novel oncoantigen upregulated in multiple types of cancers which present oncogenic activity and high immunogenicity. However, the function and therapeutic potential of DEPDC1 in hepatocellular carcinoma (HCC) remain unclear. In the present study, we showed that DEPDC1 was frequently upregulated in HCC and associated with cancer diagnosis and poor prognosis for HCC patients. Moreover, DEPDC1 promotes HCC cell proliferation in vitro as well as carcinogenesis in vivo. Notably, DEPDC1 overexpression also increases the neoplasm metastasis ability of HCC cells both in vivo and in vitro. Gene set enrichment analysis results showed that DEPDC1 expression is positively correlated with K‐RAS signal pathway, pathways in cancer and WNT/β‐catenin signal pathway, all of which are closely associated with specific cancer‐related gene sets. Our study provides the basis for further investigation of the molecular mechanism by which DEPDC1 promotes the development and metastasis of HCC.

DEPDC1 drives hepatocellular carcinoma cell proliferation, invasion and angiogenesis by regulating the CCL20/CCR6 signaling pathway

“…DEPDC1 downregulation also significantly inhibited tumourigenesis in xenograft mouse models, which may be due to the inhibition of cell proliferation and colony formation. Consistent with these results, Qu et al (13) demonstrated that DEPDC1 knockdown inhibited HCC cell proliferation, colony formation, migration and invasion. In addition, DEPDC1 silencing via siRNA reduced the viability and invasion capability of prostate cancer cell lines (24), while DEPDC1 upregulation promoted prostate cancer cell proliferation and metastases (25).…”

“…Furthermore, DEPDC1 was revealed to be involved in the miR-130a-induced apoptosis and inhibition of proliferation in HepG2 cells (12). Qu et al (13) revealed that DEPDC1 promoted HCC cell proliferation and neoplasm metastasis. The present study also determined that DEPDC1 was positively correlated with the K-RAS signaling pathway, certain cancer-associated pathways and the WNT/β-catenin signaling pathway.…”

“…Furthermore, a previous study revealed that disrupting the DEPDC1-ZNF224 complex via the 1R-DEP peptide induced apoptosis and inhibited the proliferation of HepG2 cells (12). Qu et al (13) demonstrated that DEPDC1 upregulation induced HCC cell proliferation and neoplasm metastasis. The present study revealed that DEPDC1 knockdown significantly suppressed HCC cell proliferation, colony formation and invasion, and DEPDC1 overexpression significantly induced HCC cell proliferation, colony formation and invasion.…”

Comprehensive Analysis of lncRNA-Mediated ceRNA Crosstalk and Identification of Prognostic Biomarkers in Wilms’ Tumor

“…Among these DEmRNAs, we found that high DEPDC1 and CEP55 expression was associated with poor prognosis in patients with WT based on our survival analysis results. Several studies showed that the DEP domain containing 1 (DEPDC1) protein was a novel oncoantigen that was aberrantly overexpressed in multiple types of cancers [28,29]. DEPDC1 was shown to be negatively regulated by miR-26b and promoted cell proliferation and tumor growth by upregulating FOXM1 expression in triple-negative breast cancer [30].…”

MicroRNA‐374c‐5p inhibits the development of breast cancer through TATA‐box binding protein associated factor 7‐mediated transcriptional regulation of DEP domain containing 1

“…DEPDC1 was selected as it was claimed to play an oncogenic function in carcinomas 19,22,25 and affect biological activities, such as cell proliferation, 22 apoptosis, 21 and metastasis. 18 As exhibited in Figure 3A, we obtained the predicted transcriptional regulation of TAF7 on DEPDC1 from UCSC Genome Browser. The result of luciferase reporter assay validated the upregulation of TAF7 purely enhanced the luciferase activity of WT DEPDC1 promoter ( Figure 3B).…”